Patient selection: EGFR mutant non-small cell lung cancer
Parameters:
(1) total white blood cell count in 10^9/L, enter from 0 to 110
(2) hemoglobin in g/dL, from 8 to 19
(3) serum LDH in U/L at EGFR TKI treatment, from 200 to 1400
(4) neutrophil to lymphocyte ratio (NLR), from 0 to 50
(5) race
(6) Karnofsky performance status
(7) Charlson comorbidity index (CCI)
(8) neurological symptoms
(9) brain metastases
(10) pleural metastases
(11) adrenal metastases
points for WBC count =
= (0.2166 * (WBC))
points for hemoglobin =
= 23.2145 - (1.2218 * (hemoglobin))
points for serum LDH =
= (0.0833 * (LH)) - 16.6667
points for NLR =
= (0.1254 * (NLR))
|
Parameter
|
Finding
|
Points
|
|
race
|
Chinese
|
4.48
|
|
|
non-Chinese
|
0
|
|
Karnofsky PS
|
90 to 100
|
0
|
|
|
70 to 80
|
3.14
|
|
|
less than 60
|
42.11
|
|
Charlson comorbidity
|
0
|
0
|
|
|
1
|
3.14
|
|
|
2
|
6.54
|
|
|
>=3
|
9.86
|
|
neurological symptoms
|
no
|
0
|
|
|
yes
|
3.58
|
|
brain metastases
|
no
|
0
|
|
|
yes
|
35.39
|
|
pleural metastases
|
no
|
0
|
|
|
yes
|
56
|
|
adrenal metastases
|
no
|
0
|
|
|
yes
|
19.26
|
where:
• The CCI for nonmetastatic cancer is 2. This would mean that the minimum in this population is 2, unless it refers to non-malignant CCI.
total score =
= SUM(points for all 11 parameters)
Interpretation:
• minimum score: 0
• maximum score: 313.3
• The higher the score the worse the prognosis.
• The greater the time after diagnosis the worse the prognosis.
|
Score
|
12-Month Overall Survival
|
|
< 13.8
|
> 80%
|
|
13.8 to 168.4
|
(-0.000002053 * ((score)^2)) - (0.000919 * (score)) + 0.8131
|
|
> 168.4
|
< 60%
|
